Trial intelligence / Profile preview

LNL Therapy for Advanced HER2-Negative Breast Cancer

NCT05981001Phase 2Recruiting

Sponsor
Sun Yat-sen Memorial Hospital
Start
Aug 2023
Primary completion
Apr 2032
Modality
Adoptive Cell Transfer
Countries
1
01

Overview

A Phase 2 trial of tumor-draining lymph node-derived lymphocytes in breast cancer, sponsored by Sun Yat-sen Memorial Hospital. Started Aug 2023; status: recruiting.

02

Drugs

tumor-draining lymph node-derived lymphocytes
03

Conditions

breast cancer

Beyond the preview

Go deeper on NCT05981001.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT05981001.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call